SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

🌍 Introduction: A Legendary Icon, Reimagined for the Future The SEAMANIA Protocol, led by SEAMAN Cult, aims to revive one of SEGA Dreamcast's most iconic and best-selling game titles with AI integration—a worldwide cultural phenomenon that won numerous awards in the U.S. and Japan. More than just a game, SEAMAN was the world’s first AI-powered interactive experience, enabling voice-based conversations long before the AI revolution.    Now, SEAMAN returns not as a mere game, but as an advanced AI agent, blending nostalgia with cutting-edge technology. This human-faced fish is reborn as a deeply intelligent, emotionally responsiveAI, offering limitless customization and integration into the modern digital world.  With GenAI-powered customization, users can create their own SEAMAN AI, shaping it into a cherished lostone, a favorite celebrity, or even historical figures. This is no longer a game—it's an AI-driven personal companion and the digital evolution for human interaction.    🔥 Concept: The Wisdom of a Legendary AI-powered Companion At the core of the SEAMANIA Protocol lies the legendary Seaman—a mystical, human-faced fish endowed withancient wisdom and the ability to understand human language. More than just an AI, it is your trustedadvisor, best friend, therapist, personal cheerleader, witty conversationalist, intelligent guide, SEAMANIA is a life coach. Housed in your own digital aquarium, your SEAMAN AI reduces stress, combats loneliness, and guides humanity towards a brighter future. Imagine an AI companion that doesn’t just respond but truly understands, entertains, and supports you—blending humor, sarcasm, and wisdom.

SEAMANIA

SEAMANIA is trending as the community aggressively promotes the meme coin through coordinated buying campaigns and social media outreach to drive rapid price appreciation. Participants are actively debating whether to hold through volatility, fueled by speculation that the token is poised for significant gains compared to other trending small-cap crypto assets.

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. The firm's pipeline includes clinical stage development programs, including a FXR agonist, a VAP-1 inhibitor, a THR-ß agonist, and a preclinical GLP-1 receptor agonist program. The company was founded by Randall L. Halcomb, Martijn Fenaux, and Weidong Zhong in 2017 and is headquartered in Foster City, CA.

Terns Pharmaceuticals Inc

Terns Pharmaceuticals is experiencing significant market interest driven by positive clinical data for its lead oncology asset, TERN-701, which has fueled speculation regarding a potential buyout or strategic partnership. While the stock has seen a substantial rally, community discussion remains polarized, with some investors celebrating the promising efficacy and best-in-disease potential, while others express caution over the company's valuation, cash burn, and the typical volatility associated with early-stage biotech assets.

Far below the surface, where light no longer reaches and noise collapses into silence, the Sperm Whale endures.  It does not rely on speed or spectacle. It survives through mass, intelligence, and absolute awareness of its surroundings.  This project is shaped by the same principle — strength formed under pressure, movement guided by understanding, and conviction built where others cannot remain.  While the surface reacts, the deep decides.

The Sperm Whale

SPERMWHALE is trending as traders speculate on a potential parabolic run, drawing significant attention due to its volatile chart patterns and rapid gains. While community members debate whether this is a legitimate long-term play or a classic pump-and-dump scheme, many are actively monitoring its price action for signs of an impending breakout.

Arm Holdings Plc engages in the licensing, marketing, research, and development of microprocessors, systems IP, graphics processing units, physical IP and associated systems IP, software, and tools. It operates through the following geographical segments: United Kingdom, United States, and Other Countries. The company was founded on November 12, 1990 and is headquartered in Cambridge, the United Kingdom.

Arm Holdings plc. - ADR

Arm Holdings Plc.

Arm Holdings is drawing intense investor focus as the market closely monitors the company's transition from mobile architecture to a central role in AI data center CPUs, with the upcoming earnings report acting as a critical catalyst. While community sentiment is divided between skepticism over its premium valuation and optimism regarding its long-term potential in high-margin sectors like robotics and AGI, traders are actively positioning for significant volatility around the announcement.

Cleveland-Cliffs, Inc. is a flat-rolled steel company, which engages in provision of iron ore pellets to the North American steel industry. It focuses on the production of metallic and coke, iron making, steelmaking, rolling and finishing, and downstream tubular components, stamping, and tooling. It operates through the Steelmaking and Other Businesses segments. The company was founded in 1847 and is headquartered in Cleveland, OH.

Cleveland-Cliffs Inc

Cleveland-Cliffs is currently experiencing heightened volatility and intense community debate following significant insider stock sales by the CEO and a challenging earnings report. While bearish sentiment focuses on long-term debt and potential management misalignment, bullish investors are betting on a structural turnaround, citing strong forward HRC steel demand, potential POSCO partnership catalysts, and the company's vertically integrated supply chain as indicators for a major valuation re-rating.

Intuitive Machines, Inc. is a space exploration, infrastructure, and services company, which engages in contributing to the establishment of cislunar infrastructure and helping to develop cislunar and deep space commerce. It offers space products and services. The company was founded by Stephen J. Altemus, Kam Ghaffarian, and Timothy P. Crain in 2013 and is headquartered in Houston, TX.

Intuitive Machines Inc - Ordinary Shares - Class A

Intuitive Machines Inc

Intuitive Machines is trending as the community closely monitors NASA's strategic shift toward a phased lunar base and the anticipated LTV contract award. Investors are actively debating the long-term growth implications of this infrastructure pivot while navigating significant stock volatility.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Merck & Co Inc

Merck is attracting significant market attention as it seeks strategic oncology acquisitions to bolster its pipeline and mitigate the long-term impact of its primary blockbuster drug's patent expiration. The company is actively positioning itself for future growth through potential M&A activity, with the community closely tracking the broader pharmaceutical landscape and speculating on which biotech assets Merck may prioritize next.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending following multiple analyst price target increases and robust clinical data from its Investor Day, highlighting strong Phase 2 results in axial spondyloarthritis and promising long-term Phase 3 data in hidradenitis suppurativa. The community is vigorously discussing the stock's significant undervaluation and alleged market manipulation, despite the positive readouts and progress towards regulatory submission.

Bittensor is an open-source protocol that powers a decentralized, blockchain-based machine learning network. Machine learning models train collaboratively and are rewarded in TAO according to the informational value they offer the collective. TAO also grants external access, allowing users to extract information from the network while tuning its activities to their needs.  Ultimately, BitTensors vision is to create a pure market for artificial intelligence, an incentivized arena in which consumers and producers of this valuable commodity can interact in a trustless, open and transparent context.  Bittensor enables:  -A novel, optimized strategy for the development and distribution of artificial intelligence technology by leveraging the possibilities of a distributed ledger. Specifically, its facilitation of open access/ownership, decentralized governance, and the ability to harness globally-distributed resources of computing power and innovation within an incentivized framework.  -An open-source repository of machine intelligence, accessible to anyone, anywhere, thus creating the conditions for open and permission-less innovation on a global internet scale.  -Distribution of rewards and network ownership to users in direct proportion to the value they have added.

Bittensor

Bittensor (TAO) is trending as investors debate whether the asset represents a long-term infrastructure play for decentralized AI or a speculative bubble, with sentiment currently driven by a mix of excitement over its upcoming halving and concern regarding its recent price volatility. Community discourse remains polarized, as supporters frequently compare its scarcity model to Bitcoin and point to rapid subnet growth, while skeptics warn that the token is currently overextended and lacks sufficient real-world product adoption to justify current valuations.

Venture Global, Inc. engages in the provision of United States liquefied natural gas sourced from resource rich North American natural gas basins. It operates through the following segments: Calcasieu Project, Plaquemines Project, CP2 Project, and Sales and shipping. The company was founded by Michael Sabel and Robert Pender in 2023 and is headquartered in Arlington, VA.

Venture Global Inc. - Ordinary Shares - Class A

Venture Global Inc

Venture Global is trending as investors capitalize on a significant disruption in the global LNG market caused by infrastructure damage in Qatar, which analysts expect will drive a long-term supply shortage. The community is actively debating the stock's potential for a short squeeze and long-term valuation growth, with many highlighting the company's favorable positioning compared to international peers.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Best Penny Stocks To Watch Now - November 17th

Leap Therapeutics, Autonomix Medical, Cypherpunk Technologies, Annovis Bio, and Datavault AI are the five Penny stocks to watch today, according to MarketBeat's stock screener tool. Penny stocks are...

Autonomix Medical, Inc. (AMIX) Upgraded to Strong Buy: Here's Why

Autonomix Medical, Inc. (AMIX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

AMIX Stock May Climb Following Key U.S. Patent for Nerve-Sensing Tech

Monte Rosa Therapeutics Inc. (<a class="mention" data-mention="$GLUE" data-symbol-id="GLUE" href="https://stocktwits.com/symbol/GLUE" target="_blank">$GLUE</a>)<figure class="image"><a href="https://stocktwits.com/symbol/GLUE"><img style="aspect-ratio:1284/287;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_10_28_132438_e581646ba1.png" alt="Screenshot 2024-10-28 132438.png" width="1284" height="287"></a><figcaption>Monte Rosa Therapeutic's sentiment meter as of 1:25 p.m. ET on Oct. 28, 2024 | Source: Stocktwits</figcaption></figure>Shares of Monte Rosa Therapeutics surged over 130% on Monday, reaching a two-year high of $12.15 after&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/glue-stock-enthralls-retail-with-novartis-licensing-deal/cJ2rnM9RJW">announcing an exclusive global licensing agreement with Novartis AG ($NVS).</a>&nbsp;The collaboration focuses on developing innovative treatments for immune-related conditions, particularly MRT-6160, an oral drug designed to inhibit the degradation of VAV1, a key signaling protein for T and B cell receptors.&nbsp;As part of the agreement, Novartis will pay $150 million upfront for exclusive worldwide rights to MRT-6160 and other VAV1-targeting molecular glues, with Monte Rosa eligible for up to $2.1 billion in milestones and tiered royalties on international sales.Retail sentiment on Stocktwits surged to ‘extremely bullish’ (97/100) with ‘extremely high’ (97/100) message volume.Evoke Pharma Inc. (<a class="mention" data-mention="$EVOK" data-symbol-id="EVOK" href="https://stocktwits.com/symbol/EVOK" target="_blank">$EVOK</a>)<figure class="image"><a href="https://stocktwits.com/symbol/EVOK"><img style="aspect-ratio:1282/282;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_10_28_132459_473ee74b09.png" alt="Screenshot 2024-10-28 132459.png" width="1282" height="282"></a><figcaption>Evoke Pharma's sentiment meter as of 1:25 p.m. ET on Oct. 28, 2024 | Source: Stocktwits</figcaption></figure>Evoke Pharma’s shares were up over 30% on Monday following its presentation of&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/evoke-pharma-stock-spikes-higher-on-study-data/cJ2rllaRJO">positive data for its lead drug</a>, Gimoti, as a treatment option for diabetes gastroparesis.The company ranked among the top 10 trending stocks on Stocktwits, secured the second spot for most watched, and was listed in the top 20 most active stocks&nbsp;on Monday afternoon.Evoke Pharma and its partner, Eversana, found that patients using Gimoti, a nasal version of metoclopramide, experienced significant improvements compared to those using the oral formulation. Patients who received the nasal treatment had reduced healthcare resource use and fewer healthcare visits.Retail sentiment on Stocktwits surged into ‘extremely bullish’ territory (97/100) with ‘extremely high’ (97/100) message volume.Autonomix Medical Inc. (<a class="mention" data-mention="$AMIX" data-symbol-id="AMIX" href="https://stocktwits.com/symbol/AMIX" target="_blank">$AMIX</a>)<figure class="image"><a href="https://stocktwits.com/symbol/AMIX"><img style="aspect-ratio:1271/277;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_10_28_132518_8d6392edf1.png" alt="Screenshot 2024-10-28 132518.png" width="1271" height="277"></a><figcaption>Autonomix Medical's sentiment meter as of 1:25 p.m. ET on Oct. 28, 2024 | Source: Stocktwits</figcaption></figure>Shares of Autonomix skyrocketed by more than 90% on Monday morning following the&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/autonomix-stock-rallies-on-strong-trial-results/cJ2rlAHRJf">announcement of positive results from its clinical trial</a> aimed at alleviating pain in pancreatic cancer patients.&nbsp;The stock became the second-highest trending on Stocktwits, just behind Trump Media &amp; Technology Group Corp. ($DJT), and was listed among the top 10 most watched stocks of the day.Retail sentiment on Stocktwits surged to ‘extremely bullish’ (97/100) with chatter escalating into ‘extremely high’ (97/100) territory.For updates and corrections email newsroom@stocktwits.com.Read more: <a href="https://stocktwits.com/news-articles/markets/equity/mstr-stock-hits-all-time-high-as-btc-crosses-68000/cJ2rj2hRJ9">MicroStrategy’s Bitcoin Holdings Drive Historic High: Retail Unfazed</a>

Retail is most bullish on these stocks today | Source: Pexels

Monte Rosa Therapeutics, Evoke Pharma, and Autonomix Medical: The Top 3 Stocks Capturing Retail Attention

Retail sentiment was particularly strong for healthcare stocks today, as Monte Rosa, Autonomix, and Evoke Pharma each announced positive developments regarding their respective innovations.

Equity

Retail sentiment was particularly strong for healthcare stocks today, as Monte Rosa, Autonomix, and Evoke Pharma each announced positive developments regarding their respective innovations.


Shares of Autonomix Medical Inc. (<a class="mention" data-mention="$AMIX" data-symbol-id="AMIX" href="https://stocktwits.com/symbol/AMIX" target="_blank">$AMIX</a>) soared by over 90% on Monday morning after the company reported positive results from its clinical trial focused on managing pain in pancreatic cancer patients.It ranked as the second-highest trending stock on Stocktwits on Monday, trailing only Trump Media &amp; Technology Group Corp. (<a class="mention" data-mention="$DJT" data-symbol-id="DJT" href="https://stocktwits.com/symbol/DJT" target="_blank">$DJT</a>), and was also among the top 10 most watched stocks.The trial employs an innovative technique to target and ablate the nerves responsible for pain in late-stage pancreatic cancer patients.&nbsp;Early results from the first five participants, known as the "lead-in" cohort, have been promising, with all reporting significant pain relief after the procedure.Set to conclude by the end of 2024, the trial seeks to provide an alternative to opioid pain management, which poses risks of addiction and overdose.Autonomix's technology features a catheter-based microchip sensing array antenna, which can detect neural signals more sensitively than current technologies. This precision-guided approach is intended to diagnose and treat issues related to the peripheral nervous system.To further enhance the trial, the company plans to enroll 20 additional patients, focusing on those experiencing higher levels of pain.<figure class="image"><a href="https://stocktwits.com/symbol/AMIX"><img style="aspect-ratio:1285/291;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_10_28_103029_e257a3d1ef.png" alt="Screenshot 2024-10-28 103029.png" width="1285" height="291"></a><figcaption>Autonomix Medical's sentiment meter as of 10:30 a.m. ET on Oct. 28, 2024 | Source: Stocktwits</figcaption></figure>Retail sentiment on Stocktwits shot up to ‘extremely bullish’ (89/100) from ‘neutral’ a day ago accompanied by ‘extremely high’ (92/100) chatter.&nbsp;On Thursday last week, Autonomix completed a 1-for-20 reverse stock split. Every 20 shares were combined into one share, reducing the total number of outstanding shares from about 23 million to around 1.15 million.Autonomix’s stock has been struggling since its listing in February, earlier this year. It saw highs of $152 and has since lost 86% of its value.For updates and corrections email newsroom@stocktwits.com.Read more:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/biontech-stock-falls-after-fda-concerns/cJ22FLsRIs">BioNTech Stock Dips On FDA Concerns Over Cancer Drug Trial: Retail Response Mixed</a>

Autonomix Medical reported positive preliminary results from its ongoing proof-of-concept human clinical trial. | Source: Pexels

Autonomix’s Stock Rallies on Strong Trial Results: Retail Sentiment Soars

Autonomix’s stock has been struggling since its listing in February, earlier this year. It saw highs of $152 and has since lost 86% of its value. Monday’s surge in share price comes after the company completed a 1-for-20 reverse stock split on Thursday.

This account has been verified as an official AMIX representative.

Verified Account

Autonomix Medical

Autonomix Medical, Inc. is a development stage medical device development company focused on advancing innovative technologies for sensing and treating disorders relating to the nervous system. Its technology platform includes a catheter-based microchip-enabled array that can detect and differentiate neural signals with a high degree of sensitivity as demonstrated in animal studies. The company was founded by Robert Schwartz, Landy Toth, David A. Robins, and Robert A. Van Tassel on June 10, 2014 and is headquartered in The Woodlands, TX.

AMIX
Autonomix Medical Inc.

Feed

News

Sentiment

Fundamentals

Info

Latest AMIX News

AMIXAutonomix Medical Inc.